Global Large Molecule Injectable Drugs 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR122410046

Publication Date:

December 20, 2024

Pages:

110

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Large Molecule Injectable Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Large molecules (biologics), also called biopharmaceuticals, are a type of drugs. These are based on proteins which have a therapeutic effect.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report includes an overview of the development of the Large Molecule Injectable Drugs industry chain, the market status of Hospital Pharmacies (Intravenous Injection, Muscle Injection), Retail Pharmacies (Intravenous Injection, Muscle Injection), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Large Molecule Injectable Drugs.
Regionally, the report analyzes the Large Molecule Injectable Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Large Molecule Injectable Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Large Molecule Injectable Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Large Molecule Injectable Drugs industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Intravenous Injection, Muscle Injection).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Large Molecule Injectable Drugs market.
Regional Analysis: The report involves examining the Large Molecule Injectable Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Large Molecule Injectable Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Large Molecule Injectable Drugs:
Company Analysis: Report covers individual Large Molecule Injectable Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Large Molecule Injectable Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacies, Retail Pharmacies).
Technology Analysis: Report covers specific technologies relevant to Large Molecule Injectable Drugs. It assesses the current state, advancements, and potential future developments in Large Molecule Injectable Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Large Molecule Injectable Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Large Molecule Injectable Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Intravenous Injection
Muscle Injection
Subcutaneous Injection
麻豆原创 segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
麻豆原创 segment by players, this report covers
Biogen
AstraZeneca
Roche
Sun Pharmaceutical
Medtronic
Novartis
鈥嬧赌婤补虫迟别谤
Amgen
Pfizer
Johnson & Johnson
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Large Molecule Injectable Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Large Molecule Injectable Drugs, with revenue, gross margin and global market share of Large Molecule Injectable Drugs from 2019 to 2024.
Chapter 3, the Large Molecule Injectable Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Large Molecule Injectable Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Large Molecule Injectable Drugs.
Chapter 13, to describe Large Molecule Injectable Drugs research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Large Molecule Injectable Drugs
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Large Molecule Injectable Drugs by Type
1.3.1 Overview: Global Large Molecule Injectable Drugs 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Large Molecule Injectable Drugs Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Intravenous Injection
1.3.4 Muscle Injection
1.3.5 Subcutaneous Injection
1.4 Global Large Molecule Injectable Drugs 麻豆原创 by Application
1.4.1 Overview: Global Large Molecule Injectable Drugs 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Global Large Molecule Injectable Drugs 麻豆原创 Size & Forecast
1.6 Global Large Molecule Injectable Drugs 麻豆原创 Size and Forecast by Region
1.6.1 Global Large Molecule Injectable Drugs 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Large Molecule Injectable Drugs 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Large Molecule Injectable Drugs 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Large Molecule Injectable Drugs 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Large Molecule Injectable Drugs 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Large Molecule Injectable Drugs 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Large Molecule Injectable Drugs 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Large Molecule Injectable Drugs Product and Solutions
2.1.4 Biogen Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Biogen Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Large Molecule Injectable Drugs Product and Solutions
2.2.4 AstraZeneca Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Large Molecule Injectable Drugs Product and Solutions
2.3.4 Roche Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Roche Recent Developments and Future Plans
2.4 Sun Pharmaceutical
2.4.1 Sun Pharmaceutical Details
2.4.2 Sun Pharmaceutical Major Business
2.4.3 Sun Pharmaceutical Large Molecule Injectable Drugs Product and Solutions
2.4.4 Sun Pharmaceutical Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Sun Pharmaceutical Recent Developments and Future Plans
2.5 Medtronic
2.5.1 Medtronic Details
2.5.2 Medtronic Major Business
2.5.3 Medtronic Large Molecule Injectable Drugs Product and Solutions
2.5.4 Medtronic Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Medtronic Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Large Molecule Injectable Drugs Product and Solutions
2.6.4 Novartis Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Novartis Recent Developments and Future Plans
2.7 鈥嬧赌婤补虫迟别谤
2.7.1 鈥嬧赌婤补虫迟别谤 Details
2.7.2 鈥嬧赌婤补虫迟别谤 Major Business
2.7.3 鈥嬧赌婤补虫迟别谤 Large Molecule Injectable Drugs Product and Solutions
2.7.4 鈥嬧赌婤补虫迟别谤 Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 鈥嬧赌婤补虫迟别谤 Recent Developments and Future Plans
2.8 Amgen
2.8.1 Amgen Details
2.8.2 Amgen Major Business
2.8.3 Amgen Large Molecule Injectable Drugs Product and Solutions
2.8.4 Amgen Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Amgen Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Large Molecule Injectable Drugs Product and Solutions
2.9.4 Pfizer Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Johnson & Johnson
2.10.1 Johnson & Johnson Details
2.10.2 Johnson & Johnson Major Business
2.10.3 Johnson & Johnson Large Molecule Injectable Drugs Product and Solutions
2.10.4 Johnson & Johnson Large Molecule Injectable Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Johnson & Johnson Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Large Molecule Injectable Drugs Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Large Molecule Injectable Drugs by Company Revenue
3.2.2 Top 3 Large Molecule Injectable Drugs Players 麻豆原创 Share in 2023
3.2.3 Top 6 Large Molecule Injectable Drugs Players 麻豆原创 Share in 2023
3.3 Large Molecule Injectable Drugs 麻豆原创: Overall Company Footprint Analysis
3.3.1 Large Molecule Injectable Drugs 麻豆原创: Region Footprint
3.3.2 Large Molecule Injectable Drugs 麻豆原创: Company Product Type Footprint
3.3.3 Large Molecule Injectable Drugs 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Large Molecule Injectable Drugs Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Large Molecule Injectable Drugs 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Large Molecule Injectable Drugs Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Large Molecule Injectable Drugs 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Large Molecule Injectable Drugs Consumption Value by Type (2019-2030)
6.2 North America Large Molecule Injectable Drugs Consumption Value by Application (2019-2030)
6.3 North America Large Molecule Injectable Drugs 麻豆原创 Size by Country
6.3.1 North America Large Molecule Injectable Drugs Consumption Value by Country (2019-2030)
6.3.2 United States Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Large Molecule Injectable Drugs Consumption Value by Type (2019-2030)
7.2 Europe Large Molecule Injectable Drugs Consumption Value by Application (2019-2030)
7.3 Europe Large Molecule Injectable Drugs 麻豆原创 Size by Country
7.3.1 Europe Large Molecule Injectable Drugs Consumption Value by Country (2019-2030)
7.3.2 Germany Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Large Molecule Injectable Drugs Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Large Molecule Injectable Drugs Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Large Molecule Injectable Drugs 麻豆原创 Size by Region
8.3.1 Asia-Pacific Large Molecule Injectable Drugs Consumption Value by Region (2019-2030)
8.3.2 China Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Large Molecule Injectable Drugs Consumption Value by Type (2019-2030)
9.2 South America Large Molecule Injectable Drugs Consumption Value by Application (2019-2030)
9.3 South America Large Molecule Injectable Drugs 麻豆原创 Size by Country
9.3.1 South America Large Molecule Injectable Drugs Consumption Value by Country (2019-2030)
9.3.2 Brazil Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Large Molecule Injectable Drugs Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Large Molecule Injectable Drugs Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Large Molecule Injectable Drugs 麻豆原创 Size by Country
10.3.1 Middle East & Africa Large Molecule Injectable Drugs Consumption Value by Country (2019-2030)
10.3.2 Turkey Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Large Molecule Injectable Drugs 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Large Molecule Injectable Drugs 麻豆原创 Drivers
11.2 Large Molecule Injectable Drugs 麻豆原创 Restraints
11.3 Large Molecule Injectable Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Large Molecule Injectable Drugs Industry Chain
12.2 Large Molecule Injectable Drugs Upstream Analysis
12.3 Large Molecule Injectable Drugs Midstream Analysis
12.4 Large Molecule Injectable Drugs Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Biogen
AstraZeneca
Roche
Sun Pharmaceutical
Medtronic
Novartis
鈥嬧赌婤补虫迟别谤
Amgen
Pfizer
Johnson & Johnson

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.